Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions

Autoři

BLATNÝ Jan ASTERMARK Jan CATARINO Cristina DOLAN Gerry FIJNVANDRAAT Karin HERMANS Cedric HOLSTEIN Katharina JIMENEZ-YUSTE Victor KLAMROTH Robert LAVIN Michelle LENTING Peter J LOBET Sebastien MANCUSO Maria Elisa MOTWANI Jayashree O'DONNELL James S KOENIGS Christoph

Rok publikování 2024
Druh Článek v odborném periodiku
Časopis / Zdroj THERAPEUTIC ADVANCES IN HEMATOLOGY
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://journals.sagepub.com/doi/epdf/10.1177/20406207241285143
Doi https://doi.org/10.1177/20406207241285143
Klíčová slova hemophilia; innovation; management; outcomes; quality of life
Popis Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue to drive innovation, and emerging options have the potential to realize further improvement. We advocate four general principles to optimize benefits from innovation: individualizing the treatment approach, targeting 'normal,' making the most of available resources, and considering treatment affordability. Ultimately, all PwH-men and women, of all ages and severities, and worldwide-should have access to treatment that fully prevents bleeding, while allowing personal, social, family, and professional lives of choice. Clearly, we are not there yet, but developing goals/milestones based on the principles we describe may help to achieve this.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info